RxWatch News and Information

More Generic Zantac Recalls

Lawsuit News from OnderLaw

Denton Pharma and Apco Pharma recall their ranitidine ulcer and heartburn meds.

Wednesday, January 15, 2020 - Two more companies have issued voluntary recalls after discovering that some of their heartburn and ulcer medications that contain ranitidine, the active ingredient in Zantac, had unacceptable levels of N-nitrosodimethylamine (NDMA).

Denton Pharma, dba Northwind Pharmaceuticals, has ceased distribution of 10 lots of ranitidine manufactured by Glenmark found to contain N-nitrosodimethylamine (NDMA).

Apco Pharma has also recalled eight lots of ranitidine-based medication.

The recalls are the latest among an increasingly large number of drug manufacturers who have pulled their generic Zantac products from shelves following testing by a Connecticut-based pharmacy that found NDMA in every ranitidine-based drug that it carried.

The FDA urged Zantac manufacturer Sanofi and manufacturers of generic versions of the drug to conduct their own testing. Zantac was recalled a short time later, and several major retailers, including drug and discount stores, began removing Zantac and its generic forms from their inventory. A number of companies have now followed up with recalls.

NDMA can be created during the manufacturing process, or come from solvents that are used in the process. It is believed that it can also result during storage or possibly digestion of ranitidine, as the molecules made to create it are found in the ranitidine compound.

If you have taken Zantac regularly and developed cancer, contact OnderLaw at 314-963-9000, or click here to request a free consultation. We are committed to holding companies accountable for dangerous products, and we don’t get paid unless you receive compensation.

Tags for This Article:

Zantacranitidine


More Recent Lawsuit News:

No-Cost, No-Obligation Case Review.

OnderLaw, LLC in St. Louis has developed a solid reputation of excellence as a personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. OnderLaw has represented clients throughout the United States in pharmaceutical and medical device litigation, including Pradaxa, Lexapro and Yasmin/Yaz, Actos, Risperdal and others. OnderLaw has won verdicts of more than $300 million in talcum powder ovarian cancer lawsuits and represent more Glyphosate victims than any other firm in the country.


Onder Law Trial Awards Onder Law Trial Awards Onder Law Trial Awards Onder Law Trial Awards Onder Law Trial Awards Onder Law Trial Awards Onder Law Trial Awards Onder Law Trial Awards Onder Law Trial Awards